Zacks Investment Research upgraded shares of Hutchison China MediTech Ltd – (NASDAQ:HCM) from a sell rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “

A number of other equities research analysts have also issued reports on HCM. Beaufort Securities reaffirmed a buy rating on shares of Hutchison China MediTech Ltd – in a report on Tuesday, June 21st. Canaccord Genuity reaffirmed a buy rating on shares of Hutchison China MediTech Ltd – in a report on Tuesday, August 2nd. Finally, Stifel Nicolaus set a $20.00 target price on shares of Hutchison China MediTech Ltd – and gave the stock a buy rating in a report on Monday, August 1st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $18.33.

Shares of Hutchison China MediTech Ltd – (NASDAQ:HCM) opened at 12.47 on Tuesday. Hutchison China MediTech Ltd – has a 12-month low of $9.80 and a 12-month high of $14.70. The company’s market cap is $1.51 billion. The stock has a 50 day moving average of $12.80 and a 200 day moving average of $13.13.

Large investors have recently made changes to their positions in the stock. Baillie Gifford & Co. bought a new position in shares of Hutchison China MediTech Ltd – during the second quarter valued at $1,970,000. Schroder Investment Management Group raised its position in shares of Hutchison China MediTech Ltd – by 26.6% in the second quarter. Schroder Investment Management Group now owns 416,537 shares of the company’s stock valued at $5,477,000 after buying an additional 87,485 shares during the period. Folger Hill Asset Management LP bought a new position in shares of Hutchison China MediTech Ltd – during the second quarter valued at $1,130,000. Indus Capital Partners LLC raised its position in shares of Hutchison China MediTech Ltd – by 6.3% in the second quarter. Indus Capital Partners LLC now owns 1,383,893 shares of the company’s stock valued at $18,198,000 after buying an additional 81,550 shares during the period. Finally, Societe Generale bought a new position in shares of Hutchison China MediTech Ltd – during the second quarter valued at $408,000.

About Hutchison China MediTech Ltd –

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

5 Day Chart for NASDAQ:HCM

Get a free copy of the Zacks research report on Hutchison China MediTech Ltd – (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hutchison China MediTech Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Ltd - and related companies with Analyst Ratings Network's FREE daily email newsletter.